GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MEX:MRNA) » Definitions » Price-to-Funds-From-Operations

Moderna (MEX:MRNA) Price-to-Funds-From-Operations : (As of Dec. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Moderna Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Moderna Business Description

Industry
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.